CI
Cigna Group
$286.62
+4.64 (+1.65%)
At close · Jul 7
Market Cap
$75.82B
Shares
264,532,404
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$274.9B
+11.2%
FY2025
Net Income
$5.96B
+73.5%
FY2025
Gross Margin
21.79%
-4.4pp
FY2025
Operating Margin
3.35%
-0.5pp
FY2025
Diluted EPS
$22.18
+83%
FY2025
Operating Cash Flow
$9.6B
-7.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $277.89B | $274.9B | $247.12B | $195.27B | $180.52B | $174.07B | $160.4B | $153.57B | $48.65B | $41.81B | $39.84B | |
| — | $37.34B | $40.26B | $46B | $44.24B | $39.92B | $41.15B | $42.63B | $39.71B | $36.11B | $32.49B | $30.82B | |
| — | $220.69B | $214.99B | $182.51B | $133.8B | $124.83B | $117.55B | $103.48B | $97.67B | $4.79B | $2.46B | $2.47B | |
| — | $57.2B | $59.91B | $64.61B | $61.46B | $55.68B | $56.52B | $56.92B | $55.9B | $43.86B | $39.35B | $37.37B | |
| — | — | 21.79% | 26.15% | 31.48% | 30.85% | 32.47% | 35.48% | 36.4% | 90.15% | 94.13% | 93.8% | |
| — | $14.13B | $14.62B | $14.84B | $14.82B | $13.17B | $13.01B | $14.07B | $14.05B | $11.93B | $10.03B | $9.79B | |
| — | $1.71B | $1.74B | $1.7B | $1.82B | $1.88B | $2B | $1.98B | $2.95B | $235M | $115M | $151M | |
| — | $2.75B | $2.78B | $2.78B | $3.04B | $2.94B | $2.92B | $2.8B | $3.65B | $695M | $566M | $610M | |
| — | $566M | — | $0 | $252M | $22M | $168M | — | — | — | — | — | |
| — | $9.59B | $9.2B | $9.42B | $8.54B | $8.45B | $7.94B | $8.15B | $8.08B | $4.16B | $3.94B | $3.09B | |
| — | — | 3.35% | 3.81% | 4.37% | 4.68% | 4.56% | 5.08% | 5.26% | 8.55% | 9.43% | 7.75% | |
| — | $12.34B | $11.98B | $12.19B | $11.57B | $11.39B | $10.86B | $10.96B | $11.73B | $4.86B | $4.51B | $3.7B | |
| — | -$1.4B | -$1.41B | -$1.44B | -$1.45B | -$1.23B | -$1.21B | -$1.44B | -$1.68B | -$498M | -$252M | -$278M | |
| — | $8.4B | $7.78B | $5.27B | $5.51B | $8.4B | $6.79B | $10.87B | $6.57B | $3.58B | $3.61B | $2.98B | |
| — | $1.66B | $1.49B | $1.49B | $141M | $1.62B | $1.37B | $2.38B | $1.45B | $935M | $1.37B | $1.14B | |
| — | $6.29B | $5.96B | $3.43B | $5.16B | $6.78B | $5.42B | $8.49B | $5.12B | $2.65B | $2.23B | $1.84B | |
| — | — | 2.17% | 1.39% | 2.64% | 3.76% | 3.11% | 5.29% | 3.33% | 5.44% | 5.34% | 4.63% | |
| — | $452M | $331M | $344M | $208M | $78M | $50M | $31M | $16M | $9M | -$5M | -$24M | |
| — | $6.15B | — | $3.43B | $5.16B | $6.7B | $5.37B | $8.46B | $5.1B | $2.64B | $2.24B | $1.87B | |
| — | $5.28B | $5.49B | $2.96B | $4.96B | $6.11B | $5.33B | $8.54B | $5.87B | $2.25B | $2.54B | $1.74B | |
| USD/shares | — | — | $22.33 | $12.25 | $17.57 | $21.66 | $15.89 | $23.17 | $13.58 | $10.69 | $8.92 | $7.31 |
| USD/shares | at least $30.35* | — | $22.18 | $12.12 | $17.39 | $21.41 | $15.75 | $22.96 | $13.44 | $10.54 | $8.77 | $7.19 |
| shares | — | — | 268.56M | 283.22M | 296.88M | 313.07M | 340.97M | 368.39M | 379.82M | 250.23M | 255.07M | 259.65M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2016–FY2025: $37.52B in buybacks, $7.38B in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
0.36×
EV/EBIT
10.40×
P/E (TTM)
12.15×
Healthcare Plans median 39.99×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Evernorth | $234,953,000,000 | $201,973,000,000 | $153,499,000,000 | $140,335,000,000 | $131,912,000,000 | $116,334,000,000 | $109,794,000,000 | $7,065,000,000 |
| Cigna Healthcare | $47,412,000,000 | $53,118,000,000 | $51,148,000,000 | $44,911,000,000 | $44,643,000,000 | $41,265,000,000 | $39,133,000,000 | — |
| All Other Segments | $674,000,000 | $828,000,000 | $596,000,000 | $2,263,000,000 | — | — | — | — |
| Group Disability And Other | — | — | — | — | — | $5,264,000,000 | $5,182,000,000 | $5,061,000,000 |
| Health Services | — | — | — | — | — | — | $109,794,000,000 | $7,065,000,000 |
| Integrated Medical | — | — | — | — | — | — | $36,519,000,000 | $32,791,000,000 |
| International Markets | — | — | — | — | — | $6,007,000,000 | $5,659,000,000 | $5,323,000,000 |
| Other Operations Segment | — | — | $596,000,000 | $2,263,000,000 | $3,989,000,000 | $8,446,000,000 | $8,215,000,000 | — |
| US Medical | — | — | — | — | — | $38,451,000,000 | $36,519,000,000 | $32,791,000,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Product | $216,672,000,000 | $185,362,000,000 | $137,243,000,000 | $128,566,000,000 | $121,413,000,000 | $107,769,000,000 | $103,099,000,000 | $5,479,000,000 |
| Service Fees and Other Revenues | $16,921,000,000 | $14,790,000,000 | $12,619,000,000 | $10,881,000,000 | — | — | — | — |
| Service | $16,921,000,000 | $14,790,000,000 | $12,619,000,000 | $10,881,000,000 | $9,953,000,000 | $8,761,000,000 | $9,363,000,000 | $5,578,000,000 |
| Service Other | $696,000,000 | $584,000,000 | $210,000,000 | $168,000,000 | $188,000,000 | $254,000,000 | $157,000,000 | $20,000,000 |
| Home Delivery and Specialty | — | — | $65,732,000,000 | $61,283,000,000 | $54,391,000,000 | $49,906,000,000 | $49,226,000,000 | $3,997,000,000 |
| Network Pharmacy | — | — | $67,514,000,000 | $64,946,000,000 | $64,992,000,000 | $56,365,000,000 | $51,430,000,000 | $1,415,000,000 |
| Other Pharmacy | — | — | $9,047,000,000 | $6,753,000,000 | $6,428,000,000 | $5,403,000,000 | $4,900,000,000 | $67,000,000 |
| Service Fees | — | — | — | — | — | $8,532,000,000 | $9,229,000,000 | $5,558,000,000 |
Key facts
CIK
1739940
CUSIP
125523100
13F (30d)
86 filings
43 filers
Visit website
Investor relations